ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
48 announcements
Shalby Limited disclosed under Regulation 30(5) that the board authorised KMP personnel for materiality determination. Mr. Tushar Shah's designation was revised after his appointment as Executive Director.
Consolidated revenue rose 9.8%, but EBITDA grew only 0.8% and margin fell 130 bps to 14.6%. PAT was flat at ₹7.9 Cr. Standalone hospitals carry profit while subsidiaries drag. Management deflected on Mumbai, MedTech expansion and POSO revenue.
Consolidated Q2 FY27 revenue ₹3,182mn (+9.8% YoY), EBITDA flat at ₹464mn, margin 14.6%, PAT ₹79mn (+8.3%). Standalone PAT +19%; growth driven by International and occupancy.
Shalby Ltd seeks shareholder approval via postal ballot to appoint Shanay Vikram Shah and Tushar Shah as directors. E-voting runs November 5 to December 4, 2026.
Shalby Limited appointed Mr. Tushar Shah as Executive Director for five years, effective November 3, 2026, subject to shareholder approval. The change is a senior management appointment.
Shalby Ltd reported revenue from operations of ₹313.2 Cr (+9.7% YoY) and net profit of ₹7.9 Cr (+8.2% YoY) for Q2 FY27.
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Shalby Limited has scheduled a board meeting for November 3, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.
Shalby Ltd filed its quarterly shareholding pattern as of September 30, 2026, disclosing the promoter and public shareholding structure in compliance with SEBI regulations.
Shalby Limited's Jabalpur unit faces a registration suspension by local authorities following a minor fire. The company expects no material financial impact from this event.
Shareholders at the AGM did not approve the appointment of Mr. Shanay Vikram Shah as Director, resulting in his cessation from the Board effective September 10, 2026.
Shalby Limited held its 22nd Annual General Meeting on September 10, 2026. The meeting covered adoption of financial statements and appointment of a whole-time director.
Shalby Limited has issued a letter to shareholders providing the web-link for the Annual Report for FY 2025-26. The 22nd Annual General Meeting is scheduled for September 10, 2026.
Shalby Limited filed its Business Responsibility & Sustainability Report (BRSR) for FY 2025-26 as mandated by SEBI LODR regulations.
Shalby Ltd announced its 22nd Annual General Meeting scheduled for September 10, 2026, and filed its Annual Report for FY 2025-26.
Shalby reported a modest 11.6% revenue growth with its MetLife business reaching EBITDA break-even, but hospital margins remain under pressure due to new doctor recruitments.
Shalby Limited reported Q1 FY27 consolidated revenue of ₹3,386 mn, up 11.6% YoY, and PAT of ₹105 mn, up 36.7% YoY. Focus remains on orthopedic leadership and expanding implant business.
Shalby Limited appointed Mr. Shanay Vikram Shah as an Additional Director designated as Whole-Time Director, effective August 12, 2026. This follows today's board meeting.
Shalby Limited granted 15,000 employee stock options to eligible employees under its 2021 ESOP scheme, with an exercise price of ₹100 per option.
Shalby Limited appointed Mr. Shanay Vikram Shah as an Additional Director designated as Whole-Time Director for a five-year term, effective August 12, 2026. He is also designated as a Key Managerial Personnel.
Shalby Ltd reported revenue from operations of ₹331.2 Cr (+11.7% YoY) and net profit of ₹10.5 Cr (+36.4% YoY) for Q1 FY27.
Shalby Limited reported the exercise of 3,000 employee stock options on August 10, 2026. The exercise occurred via the Employee Welfare Trust, impacting no paid-up capital.
Shalby Limited approved availing working capital facilities totaling ₹129.70 crore from Kotak Mahindra Bank Limited. This includes funding for both the company and its US subsidiary.
Shalby Limited has rescheduled its board meeting from August 5, 2026, to August 12, 2026, due to unavoidable exigencies.
ICRA Limited downgraded Shalby Limited's credit rating to [ICRA]A from [ICRA]A+, while revising the outlook from Negative to Stable for ₹830 Crore of credit facilities.
Shalby Limited announced the exercise of 6,000 stock options by eligible employees under its ESOP scheme, with shares transferred from the Employee Welfare Trust.
Shalby Limited will hold a board meeting on August 5, 2026. The board will consider and approve unaudited financial results for the June 2026 quarter.
Shalby Limited announced the exercise of 20,500 employee stock options. The exercise realized ₹0.21 Crore, with shares transferred from the employee welfare trust.
Shalby Limited announced the settlement of arbitration proceedings with Dr. Viral Shah and Dr. Praveen Saxena. The disputes were disposed of with no financial impact.
Shalby Limited clarified an inadvertent EPS error in its XBRL financial results. The company corrected the labels for continued and discontinued operations.